D. Milton

发表

Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus

William Pao, Binsheng Zhao, Lawrence H Schwartz, 2007, Clinical Cancer Research.

ProspectiveAssessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by theAddition of Everolimus

L. Schwartz, Binsheng Zhao, M. Kris, 2007 .

Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence

C. Slingluff, K. Lewis, J. Travers, 2021, Journal for ImmunoTherapy of Cancer.

High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib

M. Kris, V. Miller, A. Omuro, 2005, Cancer.

Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa)

M. Kris, M. Feinstein, Jorge E Gomez, 2004, Supportive Care in Cancer.

Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.

A. Rademaker, E. Hart, T. Hensing, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.

V. Seshan, C. Rudin, M. Kris, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ASCO Provisional Clinical Opinion: Epidermal Growth Factor Receptor Mutation Testing in Practice.

M. Beasley, D. Milton, 2011, Journal of oncology practice.

美国临床肿瘤学会Ⅳ期非小细胞肺癌化疗的临床实践指南更新

Thomas J. Smith, G. Giaccone, C. Azzoli, 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Targeting Lewis Y (Ley) in Small Cell Lung Cancer with a Humanized Monoclonal Antibody, hu3S193: A Pilot Trial Testing Two Dose Levels

M. Kris, A. Scott, L. Krug, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.

G. Giaccone, M. Somerfield, H. Wakelee, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting Lewis Y (LeY) in small cell lung cancer (SCLC) with a humanized monoclonal antibody, hu3S193.

L. Krug, A. Jungbluth, E. Quaia, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC)

C. Obasaju, E. Hart, T. Hensing, 2008 .

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer.

Thomas J. Smith, G. Giaccone, C. Azzoli, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Practice Guideline Update on Chemotherapy for Stage IV Non – Small-Cell Lung Cancer

Thomas J. Smith, G. Giaccone, C. Azzoli, 2009 .

[American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer].

Thomas J. Smith, G. Giaccone, C. Azzoli, 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall‐cell lung cancer

M. Kris, C. Azzoli, W. Pao, 2007, Cancer.

Advances in cytotoxic chemotherapy for the treatment of metastatic or recurrent non-small cell lung cancer.

V. Miller, D. Milton, 2005, Seminars in oncology.

A phase I/II study of weekly high‐dose erlotinib in previously treated patients with nonsmall cell lung cancer

William Pao, M. Kris, C. Azzoli, 2006, Cancer.

Docetaxel and Oxaliplatin as First-Line Therapy for Advanced Non-Small Cell Lung Cancer: A Phase II Trial

C. Nabhan, S. Hallmeyer, D. Milton, 2009, Journal of chemotherapy.

Mitomycin-C/5-fluorouracil/leucovorin and hyperfractionated radiation therapy for rectal carcinoma: a phase II study with long-term follow-up.

L. Prasad, C. Nabhan, B. Samuels, 2007, Clinical colorectal cancer.

Combined inhibition of mTOR and EGFR with everolimus (RAD001) and gefitinib in patients with non-small cell lung cancer who have smoked cigarettes: A phase II trial

M. Kris, C. Azzoli, W. Pao, 2007 .

Weekly high-dose erlotinib in patients with non-small cell lung cancer (NSCLC): A phase I/II study.

M. Kris, C. Azzoli, V. Miller, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC)

M. Kris, C. Azzoli, W. Pao, 2005 .

American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.

Thomas J. Smith, G. Giaccone, C. Azzoli, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular on/off switch.

M. Kris, W. Pao, Gregory Riely, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ASCO Provisional Clinical Opinion: Epidermal Growth Factor Receptor Mutation Testing in Practice.

M. Beasley, D. Milton, 2011, Journal of oncology practice.